
Altimmune ALT
$ 4.22
1.32%
Quarterly report 2025-Q3
added 11-06-2025
Altimmune DSO Ratio 2011-2026 | ALT
Annual DSO Ratio Altimmune
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.1 K | 550 | -464 | - | 552 | 104 | 158 | 346 | 69.7 | 50.6 | 14.6 | 73.9 | 94.9 | 119 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.1 K | -464 | 1.29 K |
Quarterly DSO Ratio Altimmune
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.6 K | 7.56 K | 9.59 K | - | 7.77 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15 | 152 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.6 K | 15 | 5.95 K |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apellis Pharmaceuticals
APLS
|
115 | $ 20.41 | -1.4 % | $ 2.57 B | ||
|
Aptorum Group Limited
APM
|
20.6 | $ 0.79 | -6.51 % | $ 4.31 M | ||
|
Axsome Therapeutics
AXSM
|
105 | $ 165.07 | -0.79 % | $ 8.21 B | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
AbCellera Biologics
ABCL
|
173 | $ 3.76 | -1.7 % | $ 1.12 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Capricor Therapeutics
CAPR
|
31.9 | $ 26.36 | -1.82 % | $ 706 M | ||
|
Certara
CERT
|
89.6 | $ 7.24 | 2.62 % | $ 1.16 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Codexis
CDXS
|
32.9 | $ 1.01 | -0.98 % | $ 74.1 M | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
59.5 | $ 23.77 | -0.46 % | $ 2.91 B | ||
|
Agenus
AGEN
|
4.13 | $ 3.27 | -2.09 % | $ 1.17 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Agios Pharmaceuticals
AGIO
|
47.4 | $ 28.85 | -1.2 % | $ 1.67 B | ||
|
Champions Oncology
CSBR
|
66.5 | $ 5.98 | -1.48 % | $ 81.7 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Фармсинтез
LIFE
|
209 | - | - | - | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
Cellectis S.A.
CLLS
|
94.5 | $ 3.71 | -2.43 % | $ 116 M | ||
|
Teligent, Inc.
TLGT
|
90.7 | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
169 | - | - | $ 2.91 B | ||
|
Amarin Corporation plc
AMRN
|
213 | $ 14.3 | 2.66 % | $ 5.93 B | ||
|
AbbVie
ABBV
|
258 | $ 233.44 | -0.33 % | $ 413 B |